Business
Elanco executive appointed as Neurizon's Board Observer
Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.
About this update from Neurizon Therapeutics Limited
[{"type":"text","content":"MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.","length":584,"tagName":"p"},{"type":"text","content":"The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follows an exclusive global license agreement for Monepantel, the active pharmaceutical ingredient in NUZ-001 (refer ASX announcement: 2 July 2025). This agreement marks a major milestone for Neurizon and supports the Company's regulatory foundations, providing ongoing access to critical animal safety data and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and global market entry.","length":606,"tagName":"p"},{"type":"text","content":"Ms Conway is a seasoned healthcare professional with more than two decades of experience across the animal health and healthcare industries. She joined Elanco in 2020 as Global Head of Business Development, following an extensive investment banking career with Macquarie Bank and Bank of America Merrill Lynch, where she held senior roles across Sydney, London and New York.","length":374,"tagName":"p"},{"type":"text","content":"Her experience includes significant work across the pharmaceutical and biotech sectors, executing numerous M&A transactions and capital raisings. She has deep expertise in animal health, leading major business development initiatives, the external innovation function, and a broad range of strategic transactions. She brings a strong global network and a proven track record in advancing complex commercial partnerships, financings and M&A.","length":448,"tagName":"p"},{"type":"text","content":"As Board Observer, Ms Conway will be entitled to attend and participate in all Board and committee meetings but will not hold voting r...